B-Cell Lymphoma

The FDA approved lisocabtagene maraleucel for treatment of adults with relapsed or refractory large B-cell lymphoma after one prior therapy.

SALT LAKE CITY — Patients with relapsed or refractory large B-cell lymphoma who failed chimeric antigen receptor T-cell therapy achieved durable responses with allogeneic hematopoietic stem cell transplantation, according to study results.

In this video, Joshua Sasine, MD, PhD, discusses a set of abstracts presented at ASH that evaluated natural killer cell therapies such as FT596 and FT516 in patients with relapsed/refractory B-cell lymphoma.

More than half of patients who received a single dose of CTX110 for relapsed or refractory large B-cell lymphoma responded to therapy, according to topline data released by the agent’s manufacturer.

Kite Pharma submitted a supplemental biologics license application to the FDA that seeks expanded approval of axicabtagene ciloleucel.

A randomized phase 3 trial that evaluated tisagenlecleucel as second-line treatment of relapsed or refractory aggressive B-cell non-Hodgkin lymphoma failed to meet its primary endpoint of improved EFS, according to the agent’s manufacturer.

Most patients who received one of two investigational natural killer cell therapy regimens for relapsed or refractory B-cell lymphoma achieved complete response, according to topline data released by the agents’ manufacturer.

The FDA cleared an investigational new drug application for KITE-363, a chimeric antigen receptor T-cell therapy designed to treat adults with relapsed or refractory large B-cell lymphoma.

Four of five patients with relapsed or refractory B-cell lymphoma demonstrated complete response to an investigational anti-CD19/CD20 chimeric antigen receptor T-cell therapy, according to early data from a phase 1 trial.

Immune dysregulation resulting from high tumor burden appeared associated with poor chimeric antigen receptor T-cell expansion and resistance among patients with diffuse large B-cell lymphoma, according to study results published in Blood.